Symptoms / Diagnosis

$9M Grant Funds Study of Gut-Brain Connection in Parkinson’s Disease

A-Synuclein, Gut Dysbiosis, Gut-Brain axis, Symptoms / Diagnosis, Vagal Nerve /

Dr. Michael Kaplitt, a professor of neurological surgery at Weill Cornell Medicine and a longtime leader in developing cutting-edge surgical therapies for movement disorders, leads a team that has been awarded a three-year, $8.9 million grant from the Aligning Science Across Parkinson’s (ASAP) initiative. The grant will fund an ambitious and innovative multi-institutional collaborative effort to study […]

$9M Grant Funds Study of Gut-Brain Connection in Parkinson’s Disease Read More »

Multimodal retinal imaging to detect and understand Alzheimer’s and Parkinson’s disease

Biomarkers, Parkinson's Disease, Pre-PD, Symptoms / Diagnosis, Vision /

Retinal neurodegeneration and visual dysfunctions have been reported in a majority of Alzheimer’s and Parkinson’s patients, and, in light of the quest for novel biomarkers for these neurodegenerative proteinopathies, the retina has been receiving increasing attention as an organ for diagnosing, monitoring, and understanding disease. Thinning of retinal layers, abnormalities in vasculature, and protein deposition can be imaged at unprecedented resolution,

Multimodal retinal imaging to detect and understand Alzheimer’s and Parkinson’s disease Read More »

A blood marker for Parkinson’s Disease: Neuronal exosome-derived α-synuclein

A-Synuclein, Biomarkers, Parkinson's Disease, Pre-PD, Symptoms / Diagnosis /

To date, no reliable clinically applicable biomarker has been established for Parkinson’s disease (PD). Our results indicate that a long hoped blood test for Parkinson’s disease may be realized. We here assess the potential of pathological α-synuclein originating from neuron-derived exosomes from blood plasma as a possible biomarker. Following the isolation of neuron-derived exosomes from

A blood marker for Parkinson’s Disease: Neuronal exosome-derived α-synuclein Read More »

PPMI 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort (PPMI)

Biomarkers, iRBD, Symptoms / Diagnosis /

The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson’s disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls The overall goal of PPMI 2.0 is to identify

PPMI 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort (PPMI) Read More »

Impact of rapid eye movement sleep behavior disorder and autonomic disorders on Parkinson’s disease

Biomarkers, Dementia - Lewy Bodies, iRBD, Symptoms / Diagnosis /

This article aimed at critically reviewing the literature on the controversies about the prevalence of RBD in PD, the higher incidence of PD non-motor symptoms associated with RBD, the evidence of faster motor worsening in parkinsonian patients with this parasomnia, and the main pathophysiological hypotheses that support these findings. CLICK TO REVIEW

Impact of rapid eye movement sleep behavior disorder and autonomic disorders on Parkinson’s disease Read More »

Subtle oromotor signs in early Parkinson’s disease before clinical manifestations of dysphagia

oropharyngeal, Symptoms / Diagnosis /

Multiple lingual-waves, reverse-tongue thrust, with delayed velar control attributed to incoordinated muscular rhythm. Variable oropharyngeal transit time (0.64 to 2.25 msec) in PD ascribed to brainstem degenerative changes. Findings imply that subtle observable early oromotor signs as pre-clinical manifestation when evaluated with non-invasive, non-contrast dynamic MRI support early intervention, to prevent late-stage aspiration episodes and

Subtle oromotor signs in early Parkinson’s disease before clinical manifestations of dysphagia Read More »

Smartphone Speech Testing for Symptom Assessment in Rapid Eye Movement Sleep Behavior Disorder and Parkinson’s Disease

Biomarkers, iRBD, Pre-PD, Symptoms / Diagnosis /

We analyzed 4242 smartphone voice recordings collected in clinic and at home from 92 Controls, 112 RBD and 335 PD participants. We used acoustic signal analysis and machine learning, employing 337 features that quantify different properties of speech impairment. Using a leave-one-subject-out cross-validation scheme, we were able to distinguish RBD from controls (sensitivity 60.7%, specificity

Smartphone Speech Testing for Symptom Assessment in Rapid Eye Movement Sleep Behavior Disorder and Parkinson’s Disease Read More »

Blood Pressure Patterns in Patients with Parkinson’s Disease: A Systematic Review

Biomarkers, Cardiovascular, Pre-PD, Symptoms / Diagnosis /

Patients with Parkinson’s disease have significantly altered blood pressure patterns that carry a negative prognosis. Ambulatory blood pressure monitoring should be validated as a biomarker of PD-associated cardiovascular dysautonomia and a tool for assistingtherapeutic interventions. CLICK TO REVIEW

Blood Pressure Patterns in Patients with Parkinson’s Disease: A Systematic Review Read More »

Development of early diagnosis of Parkinson’s disease and comprehensive economic analysis of the effect of its implementation

Biomarkers, Pre-PD, Symptoms / Diagnosis /

This approach can also be used to verify blood markers identified in patients at the clinical stage of PD. It is also evident that the complex socioeconomic factors influencing the incidence of PD is different in developed versus developing countries. The societal and medical costs of Parkinson’s are huge and efforts to improve early preclinical

Development of early diagnosis of Parkinson’s disease and comprehensive economic analysis of the effect of its implementation Read More »